Adhera Therapeutics, Inc.
$0.00+0.00%(+$0.00)
TickerSpark Score
53/100
100
Valuation
40
Profitability
60
Growth
36
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATRX research report →
52-Week Range0% of range
Low $0.00
Current $0.00
High $0.01
Companyadherathera.com
Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. The company was formerly known as Marina Biotech, Inc.
- CEO
- Andrew Albert Kucharchuk
- IPO
- 1993
- Employees
- 2
- HQ
- Baton Rouge, LA, US
Price Chart
+0.00% · this period
Valuation
- Market Cap
- $722
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 8.94%
- ROIC
- 11.90%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,114,000 · 66.71%
- EPS
- $-1.18 · 90.81%
- Op Income
- $-1,618,000
- FCF YoY
- -112.78%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.73
- Avg Volume
- 247
Get TickerSpark's AI analysis on ATRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 20, 21 | Waerness Trond Kydd | other | 0 |
| Nov 5, 21 | Subhan Zahed | other | 0 |
| Jul 7, 20 | KUCHARCHUK ANDREW ALBERT | other | 0 |
| Nov 1, 19 | Stanley Rhonda L. | other | 350,000 |
| Nov 1, 19 | Stanley Rhonda L. | other | 0 |
| Apr 4, 19 | Phelan Nancy R. | other | 1,500,000 |
| Jan 15, 19 | Teague Robert Eric | other | 100,000 |
| Oct 1, 18 | Phelan Nancy R. | other | 0 |
| Oct 1, 18 | Trieu Vuong | sell | 500,000 |
| Sep 24, 18 | Teague Robert Eric | other | 0 |
Our ATRX Coverage
We haven't published any research on ATRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ATRX Report →